Neuroleptic Malignant Syndrome: The Value of Diagnostic Criteria
Rowland, Tobias Banga, Anil Ayadurai, Nirmalan
Rowland, Tobias
Banga, Anil
Ayadurai, Nirmalan
Abstract
Neuroleptic malignant syndrome (NMS) is a rare but potentially serious reaction to
antipsychotic medications. The incidence of NMS is around 0.9%,1 with an estimated
mortality of 5.6%–12%.2,3 Early recognition is key and a low index of suspicion is
required as the presentation shares symptoms with other disorders,1,4,5 which is
further compounded by a lack of definitive diagnostic criteria.
MIDER Authors
Citations
Altmetric:
Date
2018-08
Type
Report
Subject
Pharmacology, Mental health, Neurology
Citation
Rowland TA, Banga A, Ayadurai N. Neuroleptic Malignant Syndrome: The Value of Diagnostic Criteria. Prim Care Companion CNS Disord. 2018 Aug 2;20(4):17l02218. doi: 10.4088/PCC.17l02218. PMID: 30085440.
Journal / Source Title
The Primary Care Companion for CNS Disorders
DOI
10.4088/PCC.17l02218
PMID
30085440
Publisher
Physicians Postgraduate Press
Publisher’s URL
https://pubmed.ncbi.nlm.nih.gov/30085440/